OncoMatch/Clinical Trials/NCT06235697
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Is NCT06235697 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies ADT for prostate cancer.
Treatment: ADT — This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT2B, CT2C, CT3A, CT3B (NCCN classification guidelines (Version 4.2022 - May 10, 2022))
Grade: Gleason 7 (grade group 2 or 3)Gleason 4+3 (grade group 3)Gleason 8-10 (grade group 4 or 5)Primary Gleason pattern 5 (Gleason/grade group)
Participants with unfavourable risk prostate cancer are eligible according to the following NCCN classification guidelines (Version 4.2022 - May 10, 2022): • Unfavourable-intermediate risk - has one or more of the following: * 2 or 3 Intermediate Risk Factors (IRFs): cT2b-cT2c, Gleason 7 (grade group 2 or 3), and/or PSA 10-20 ng/ml; * Gleason 4+3 (grade group 3) * > 50% biopsy cores positive • High risk - has one of the following: * cT3a * Gleason 8-10 (grade group 4 or 5) * PSA > 20 ng/ml • Very-high risk - has at least one of the following: * cT3b-cT4 * Primary Gleason pattern 5 * 2 or 3 high risk features: cT3a, Gleason 8-10 (grade group 4 or 5), and/or PSA > 20 ng/ml * > 4 cores with Gleason 8-10 (grade group 4 or 5)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Cannot have received: chemotherapy
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: PARP inhibitor
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: radioligand
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: investigational drug
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
any ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
Cannot have received: prostatectomy (simple prostatectomy, radical prostatectomy)
prostatectomy (simple or radical)
Cannot have received: transurethral resection of the prostate (TURP)
transurethral resection of the prostate (TURP)
Cannot have received: steam vaporization (Rezum)
Prior steam vaporization (Rezum)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Kaiser Permanente-Deer Valley Medical Center · Antioch, California
- Kaiser Permanente Dublin · Dublin, California
- Kaiser Permanente-Fremont · Fremont, California
- Kaiser Permanente Fresno Orchard Plaza · Fresno, California
- Kaiser Permanente-Fresno · Fresno, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify